Why Outsource Clinical Trials …in Emerging Markets ?
General reasons: less investment, specific expertise, company strategy, etc.
But what about emerging markets: Less costly, Faster recruitment, better retention, Research -naÃ¯ve population, Specific populations, Universal regulations (ICH-GCP)
Optimising clinical trial outsourcing partnerships in emerging markets
Â· Building mutually beneficial relationships between vaccine manufacturers and CROs
Â· Support structures for Pharma/Biotech companies from clinical trials to market supply – what are the best practice benchmarks?
Â· How Pharma/Biotech can increase collaborative efforts with CROs to increase efficiency
Dr Eduardo Motti, Regional Head of Clinical Operations, Latin America, Pfizer
For the full presentation, click here >
For more information about the topics discussed, please click here >